Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis

O. Alfurayh, M. Sobh, Y. Barri, W. Qunibi, S. Taher

Producción científica: Articlerevisión exhaustiva

12 Citas (Scopus)

Resumen

In this work, of 51 patients treated by rHuEpo, 25 were selected for study. The selection criteria were absence of clinically evident causes of anaemia other than end-stage renal failure, such as chronic infection, active systemic disease, bleeding sites, and vitamin B12 or iron deficiencies. Serum aluminium was assessed before dialysis and the presence of aluminium overload was confirmed by a DFO test. rHuEpo was given in a dose of 50 U/kg body- weight after each dialysis session three times weekly and the response to treatment was evaluated monthly for 8 months. Our data showed significant correlation between serum aluminium and the response to rHuEpo. The response was significantly greater in those with lower serum aluminium. We conclude that the aluminium load in chronic haemodialysis patients may have an effect on the response to rHuEpo.

Idioma originalEnglish (US)
Páginas (desde-hasta)939-943
Número de páginas5
PublicaciónNephrology Dialysis Transplantation
Volumen7
N.º9
DOI
EstadoPublished - ene 1 1992
Publicado de forma externa

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Huella

Profundice en los temas de investigación de 'Aluminium overload and response to recombinant human erythropoietin in patients under chronic haemodialysis'. En conjunto forman una huella única.

Citar esto